Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
12
Recruiting, any sponsor type, condition "vasomotor symptoms"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed114
12 trials
Showing 1 to 12, recently updated first.
- Evaluation of Possible Ways the Body May Process Two Different Forms of Elinzanetant in Healthy Study ParticipantsPivotal-lookingRecruiting
BayerBayer (BAYRY)
NCT07762287 · 100 participants (planned) · Start Jul 22, 2026 · Primary completion Jan 22, 2027
Drug: Elinzanetant (BAY 3427080) treatment A; Elinzanetant (BAY 3427080) treatment B · For: Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women
Sites: Mount Royal, Canada
Yale UniversityAcademic, hospital or other
NCT06917313 · 92 participants (planned) · Start Dec 5, 2025 · Primary completion Mar 2028
Drug: Fezolinetant; Placebo · For: Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Sites: New Haven, Connecticut; Columbus, Ohio
- A Study to Confirm if Fezolinetant Helps to Reduce Hot Flashes in Indian Women Going Through MenopausePivotal-lookingRecruiting
Astellas Pharma IncAstellas (ALPMY)
NCT07829653 · 100 participants (planned) · Start Oct 23, 2026 · Primary completion Mar 31, 2028
Drug: Fezolinetant · For: Hot Flashes
Sites: Bengaluru, India
Salem Anaesthesia Pain ClinicAcademic, hospital or other
NCT05618002 · 250 participants (planned) · Start Jan 2, 2023 · Primary completion Jun 28, 2027
Drug: Lemborexant · For: Chronic Insomnia; Chronic Pain; Restless Leg Syndrome (RLS) and 6 more
Sites: Surrey, Canada
- Safety and Efficacy of Asimadoline (TP0052) in Patients With Vasomotor Symptoms (VMS).Pivotal-lookingRecruiting
Tioga PharmaceuticalsIndustry
NCT07042516 · 120 participants (planned) · Start Aug 13, 2025 · Primary completion Oct 31, 2027
Drug: Asimadoline · For: Vasomotor Symptoms
Sites: Atlanta, Georgia
- A Trial on Fezolinetant for Vasomotor Symptoms in Men Receiving Androgen Deprivation Therapy (ADT)Recruiting
Chinese University of Hong KongAcademic, hospital or other
NCT07568236 · 54 participants (planned) · Start Oct 5, 2026 · Primary completion Dec 31, 2027
Drug: Fezolinetant; Placebo · For: Vasomotor Symptoms; Prostate Cancer
Sites: Shatin, Hong Kong
Mayo ClinicAcademic, hospital or other
NCT07218445 · 40 participants (planned) · Start Apr 8, 2026 · Primary completion Sep 18, 2027
Drug: Tirzepatide; Placebo · For: Obesity; Menopause Hot Flashes
Sites: Jacksonville, Florida
Shehzad Basaria, M.D.Academic, hospital or other
NCT06957691 · 60 participants (planned) · Start Jan 14, 2026 · Primary completion Aug 31, 2028
Drug: fezolinetant - reference formulation; Placebo · For: Prostate Cancer; Prostate Cancer (Adenocarcinoma); Prostate Cancer Metastatic Disease and 16 more
Sites: Boston, Massachusetts
Mayo ClinicAcademic, hospital or other
NCT05193968 · 120 participants (planned) · Start Feb 24, 2022 · Primary completion Dec 2026
Drug: Sodium Nitroprusside; Acetylcholine and 2 more · For: Hot Flashes; Menopause; Vasomotor System; Labile
Sites: Rochester, Minnesota
Astellas Pharma Europe Ltd.Astellas (ALPMY)
NCT07602530 · 238 participants (planned) · Start Oct 23, 2025 · Primary completion Feb 28, 2027
Drug: Fezolinetant · For: Hot Flashes
Sites: Montreal, Canada; Prince Albert, Canada
University of VermontAcademic, hospital or other
NCT06972875 · 32 participants (planned) · Start Dec 18, 2025 · Primary completion Jan 2027
Drug: Fezolinetant · For: Prostate CA; Androgen Deprivation Therapy
Sites: Burlington, Vermont
Insel Gruppe AG, University Hospital BernAcademic, hospital or other
NCT06497894 · 54 participants (planned) · Start Jan 1, 2026 · Primary completion Jul 1, 2026
Drug: Hormone Replacement Therapy (HRT) · For: Insomnia; Menopause
Sites: Bern, Switzerland
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.